These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 3902203)

  • 1. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.
    Shimaoka K; Schoenfeld DA; DeWys WD; Creech RH; DeConti R
    Cancer; 1985 Nov; 56(9):2155-60. PubMed ID: 3902203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma.
    Torti FM; Shortliffe LD; Carter SK; Hannigan JF; Aston D; Lum BL; Williams RD; Spaulding JT; Freiha FS
    Cancer; 1985 Dec; 56(11):2580-6. PubMed ID: 4052935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience.
    Vrbic S; Pejcic I; Vrbic M; Filipovic S
    J BUON; 2009; 14(1):41-4. PubMed ID: 19373945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
    van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
    Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
    Lupera H; Droz JP; Piot G; Lapleige P; Fargeot P; Theodore C
    Oncology; 1989; 46(6):372-4. PubMed ID: 2587004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
    Levi JA; Fox RM; Tattersall MH; Woods RL; Thomson D; Gill G
    J Clin Oncol; 1986 Sep; 4(9):1348-55. PubMed ID: 3528404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.
    Scherübl H; Raue F; Ziegler R
    J Cancer Res Clin Oncol; 1990; 116(1):21-3. PubMed ID: 2312602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
    Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
    J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
    Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
    J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
    Ruckdeschel JC; Finkelstein DM; Ettinger DS; Creech RH; Mason BA; Joss RA; Vogl S
    J Clin Oncol; 1986 Jan; 4(1):14-22. PubMed ID: 3510278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
    Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
    J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors.
    Frame J; Kelsen D; Kemeny N; Cheng E; Niedzwiecki D; Heelan R; Lippermann R
    Am J Clin Oncol; 1988 Aug; 11(4):490-5. PubMed ID: 2841843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.